Iridex publishes MicroPulse Transscleral Laser Therapy study

Iridex (IRIX) announced the publication of a peer-reviewed study in Ophthalmology Therapy. This study highlights the sustained safety and efficacy of MicroPulse Transscleral Laser Therapy in managing both primary and secondary glaucoma over five years. Conducted by Ronald de Crom and colleagues at the University Eye Clinic Maastricht, Netherlands, this research is the first to evaluate outcomes of MicroPulse TLT over such an extended period. The study assessed 165 pre- and post-cataract eyes treated between 2016 and 2019, with 112 eyes completing the five-year follow-up. Treatment was delivered using the Iridex Cyclo G6 Laser in its MicroPulse Mode and the original MicroPulse P3 Delivery Device. Results demonstrated that MicroPulse TLT achieved significant reductions in intraocular pressurer -32.5% on average-while also enabling a significant reduction in IOP-lowering medications with a low rate of complications across a broad range of glaucoma types and severities. Additionally, over the five-year follow-up period, only 38% of eyes required retreatment.